Resolution Bioscience
Top Five Articles on GenomeWeb Last Week: Agilent, Bruker, Foundation Medicine, More
Last week, GenomeWeb's readers were most interested in Agilent Technologies announcing that it is discontinuing its Resolution Bioscience business.
For Q3, the firm said its diagnostics revenues rose 3 percent, but Resolution's kitted NGS-based companion diagnostics business hadn't developed as expected.
The firm will build liquid biopsy companion diagnostic tests that complement its tissue-based assays and are tailored for drugs developed by pharma partners.
Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M
Under the deal, expected to close in April, Agilent will pay $550 million in cash on closing and up to an additional $145 million based on future milestones.
Resolution Bioscience, Mirati Therapeutics Sign Companion Diagnostic Agreement
The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.